1. Targeting the Androgen Pathway: Current Best Practice and Future Directions

3. Introduction

4. Projections for the Annual Progression and Mortality Rates for Prostate Cancer in 2020

5. Approved and Developing Therapies for mCRPC

6. Systemic Treatment Options for mCRPC

7. Selective Inhibition of CYP17 by Abiraterone: Phase 1/2 Data

8. Abiraterone Overall Survival

9. Abiraterone Prolonged Radiographic PFS

10. Enzalutamide Overall Survival

11. Enzalutamide Prolonged the Need for Chemotherapy

12. Abiraterone and Enzalutamide: How Do We Choose?

13. Patient Factors to Consider When Choosing Therapy

14. Responsiveness to ADT and the Influence on Choice of Treatment

15. Responsiveness to ADT and the Influence on Choice of Treatment (cont)

16. Biomarkers for Response to Hormonal Therapies

17. Sequencing of Antihormonal Therapies

18. The Importance of the Multidisciplinary Approach

19. Radium-223 Plus Antihormonal Therapy

20. Examples of Novel Antihormonal Agents Under Investigation

21. STAMPEDE

22. Conclusions